| Etravirine Continues to Be Well Tolerated at 96 Weeks in Treatment-Experienced HIV Patients: Presented at IAS |
| 07/20/2009 06:21:05 PM | |
| Raltegravir Maintains Efficacy Versus Efavirenz After 144 Weeks: Presented at IAS |
| 07/20/2009 05:47:06 PM | |
| Nevirapine Equally Effective, Improves Lipids Compared With Atazanavir in HIV: Presented at IAS |
| 07/20/2009 05:32:33 PM | |
| Etravirine Offers Durable Virologic Efficacy in Patients Resistant to NNRTIs and PIs: Presented at IAS |
| 05/20/2009 03:55:24 PM | |
| Children With HIV Gain More Weight With Atypical Antipsychotics: Presented at APA |
| 05/04/2009 04:03:38 PM | |
| Better Anal Cytology Screening Practices Needed for HIV-Infected Youth: Presented at PAS |
| 05/01/2009 12:33:58 PM | |
| Human Papillomavirus Associated With Higher Risk of New HIV Infection |
| 05/01/2009 11:14:50 AM | |
| Pregabalin Fares Little Better Than Placebo in Treating HIV-Associated Neuropathy: Presented at AAN |
| 04/27/2009 05:00:21 PM | |
| Vaccinations in Children With HIV Possible if HAART is Initiated Early |
| 04/27/2009 02:21:37 PM | |
| Similar Survival Rates Among HIV-Positive, HIV-Negative Patients Following Liver Transplant |
| 04/25/2009 04:40:16 PM | |
| HAART Is Well Tolerated, Leads to Rapid Suppression of HBV Replication in HBV-HIV Coinfected Patients: Presented at EASL |
| 04/16/2009 02:24:59 PM | |
| Updated Clinical Guidelines for HIV-Associated Opportunistic Infections |
| 04/07/2009 04:32:13 PM | |
| HIV-Positive Patients Show Lower Response to Hepatitis B Vaccination Even at Double Doses: Presented at BHIVA |
| 04/06/2009 05:40:03 PM | |
| Efficacy of Maraviroc Reduced in Triple-Class-Resistant HIV-Infected Patients: Presented at BHIVA |
| 04/03/2009 02:12:12 PM | |
| Once-Daily Darunavir Effective, Well Tolerated in Treatment-Naive and Experienced HIV-Positive Patients: Presented at BHIVA |
| 04/03/2009 02:04:41 PM | |
| Daily Atazanavir/Ritonavir Reduces Limb Fat Loss in HIV Patients With Lipohypertrophy: Presented at BHIVA |
| 04/03/2009 02:00:23 PM | |
| Offering Point of Care HIV Testing Increases Test Uptake: Presented at BHIVA |
| 04/01/2009 04:00:42 PM | |
| Interleukin-2 Increases CD4 Count but Does Not Reduce Opportunistic Disease Burden in HIV-Positive Patients: Presented at BHIVA |
| 03/26/2009 10:08:36 AM | |
| Male Circumcision Reduces Risk of Genital Herpes and HPV, But Not Syphilis |
| 03/04/2009 04:04:21 PM | |
| Levels of Protease Inhibitors in Hair Can Predict Virologic Success in HIV Patients |
| 03/03/2009 04:42:05 PM | |
| P4503A Has No Effect on Clearing Methadone From the Body, Say Researchers |
| 02/17/2009 12:30:26 PM | |
| Effect of Breastfeeding vs Formula Feeding on Maternal HIV Disease Progression, Mortality, and Micronutrient Levels: Presented at CROI |
| 02/13/2009 11:30:30 AM | |
| Reverse Transcriptase Mutation Linked to Increased Risk of Virological Failure to Nevirapine in ART-Experienced Patients: Presented at CROI |
| 02/12/2009 05:40:51 PM | |
| HIV-Positive Patients With Pulmonary Tuberculosis at High Risk for Acquired Rifampicin Resistance When They Fail Standard Treatment: Presented at CROI |
| 02/12/2009 05:33:33 PM | |
| Nevirapine Noninferior to Efavirenz in Treatment-Naïve Adults in Botswana: Presented at CROI |
| 02/12/2009 05:20:36 PM | |
| Regimens Based on Efavirenz Versus Lopinavir/Ritonavir Show Equivalent Efficacy for Preventing AIDS or Death: Presented at CROI |
| 02/12/2009 05:19:04 PM | |
| Risk of AIDS or Death Linked to Later Initiation of Antiretroviral Therapy: Presented at CROI |
| 02/12/2009 05:17:04 PM | |
| Smaller Effect on Renal Function Seen With Abacavir/Lamivudine Than Tenofovir/Emtricitabine in HIV-Infected Patients: Presented at CROI |
| 02/12/2009 12:26:59 PM | |
| Ritonavir-Boosted Lopinavir Better Than Nevirapine in Women Receiving Tenofovir/Emtricitabine With Prior Exposure to Single-Dose Nevirapine: Presented at CROI |
| 02/12/2009 12:22:43 PM | |
| Efavirenz-Based Therapy With or Without Abacavir Does Not Improve High-Sensitivity CRP Levels in Treatment-Naïve Patients: Presented at CROI |
| 02/11/2009 05:47:08 PM | |
| Hormonal Contraceptives Appear Safe in Women With HIV Infection: Presented at CROI |
| 02/11/2009 05:44:39 PM | |
| No Association of Abacavir Use With Risk of Myocardial Infarction or Severe Cardiovascular Disease Events: Presented at CROI |
| 02/11/2009 05:38:15 PM | |
| Subgroup Analyses Find Raltegravir Consistent in Reducing HIV Load: Presented at CROI |
| 02/11/2009 05:35:28 PM | |
| Risk of Extensive Virological Failure With Original 3 Antiretroviral Drug Class Regimens Appears Low: Presented at CROI |
| 02/11/2009 05:33:35 PM | |
| HIV-Related Neurocognitive Impairment Remains High in the Era of HAART: Presented at CROI |
| 02/11/2009 04:20:01 PM | |
| Simplification With Fixed-Dose Tenofovir/Emtricitabine or Abacavir/Lamivudine in Adults With Suppressed HIV Replication: Presented at CROI |
| 02/11/2009 04:16:45 PM | |
| HIV Treatment During Breastfeeding Period Improves Outcomes for Mother and Infant: Presented at CROI |
| 02/11/2009 04:14:13 PM | |
| Similar Reductions in Inflammation and Endothelial Activation Seen After Initiation of Abacavir/Lamivudine or Tenofovir/Emtricitabine: Presented at CROI |
| 02/11/2009 03:24:09 PM | |
| Interleukin-2 Therapy Fails to Improve Outcomes in Patients on Antiretroviral Treatment: Presented at CROI |
| 02/10/2009 05:48:47 PM | |
| Studies Show Patients With Triple-Class Resistant HIV Have Good Long-Term Response to Raltegravir Plus Optimised Therapy: Presented at CROI |
| 02/10/2009 05:46:38 PM | |
| Response to Darunavir/Ritonavir Maintained Regardless of Treatment Adherence in Treatment-Naïve HIV Patients: Presented at CROI |
| 02/10/2009 02:08:52 PM | |
| Microbicide Gel Falls Short of Showing Significant Efficacy for Prevention of HIV Infection: Presented at CROI |
| 02/10/2009 01:54:50 PM | |
| Initiation of HAART at a CD4+ >500 Cells/mm3 Associated With Improved Survival: Presented at CROI |
| 02/10/2009 01:51:10 PM | |
| Transient Therapy During Primary HIV Infection Prolongs Total Time Off Treatment: Presented at CROI |
| 02/09/2009 05:30:10 PM | |
| Short-Course, Rifamycin-Based Regimens and Continuous Isoniazid as Effective as 6 Months of Isoniazid for Latent TB in Adults With HIV: Presented at CROI |
| 02/09/2009 04:59:19 PM | |
| Cancer Rates Similar for HIV Patients on Raltegravir as With Other Antiretroviral Drugs: Presented at CROI |
| 02/09/2009 04:40:07 PM | |
| Anti-HIV Gel Shows Promise in Large-Scale Study in Women |
| 02/06/2009 03:30:54 PM | |
| Compliance With Highly-Active Antiretroviral Therapy May Be Better Than Surgical Extirpation for Prevention of Cervical Intraepithelial Neoplasia Recurrence: Presented at SGO |
| 02/04/2009 10:46:58 AM | |
| Once-Daily Darunavir Approved in EU for Treatment-Naïve Adults |
| 01/20/2009 01:03:55 PM | |
| Kidney Transplant Survival Can Be Long-Term for People With HIV |
| 12/31/2008 10:55:24 AM | |
| FDA Approves First Nucleic Acid Test to Screen for Additional Types of HIV in Donated Blood, Tissue |
| 12/08/2008 04:34:29 PM | |
| Once-Daily Atazanavir for Treatment-Naïve Patients Approved in Scotland |
| 12/04/2008 06:30:00 PM | |
| Carrageenan-Based Microbicidal Gel Fails to Protect Women From HIV, Say Researchers |
| 12/03/2008 01:30:35 PM | |
| European Union Approves Darunavir for Treatment-Experienced Patients |
| 12/01/2008 04:29:07 PM | |
| ACP Recommends HIV Screening for All Patients, Regardless of Risk Factors |
| 11/26/2008 10:04:24 AM | |
| FDA Grants Full Approval of Maraviroc for Treatment-Experienced Patients With HIV |
| 11/14/2008 12:19:36 PM | |
| Percutaneous Coronary Intervention Safe in Patients Infected With HIV: Presented at AHA |
| 11/06/2008 01:05:23 PM | |
| HIV Drug Etravirine Does Not Appear to Cause Hepatotoxicity: Presented at AASLD |
| 11/03/2008 12:53:50 PM | |
| AAP Statement Recommends Prenatal Testing, Immediate Intervention to Prevent Mother-to-Child HIV Transmission |
| 10/30/2008 10:58:27 AM | |
| Long-Term Results With Vicriviroc Show Decreasing Evidence of Malignancy: Presented at ICAAC/IDSA |
| 10/30/2008 09:35:41 AM | |
| Atazanavir/Ritonavir Noninferior to Lopinavir/Ritonavir Over 96 Weeks in Treatment-Naïve HIV Patients: Presented at ICAAC/IDSA |
| 10/29/2008 04:21:54 PM | |
| HIV Patients at High Risk for Hospitalisation Up to 90 Days After Starting Antiretroviral Therapy: Presented at ICAAC/IDSA |
| 10/29/2008 03:43:55 PM | |
| Boosted Saquinavir Appears Safe, Effective in HIV-Infected Pregnant Women: Presented at ICAAC/IDSA |
| 10/28/2008 05:48:31 PM | |
| Raltegravir Proven Noninferior to Efavirenz in HIV Patients Naïve to Antiretroviral Therapy: Presented at ICAAC/IDSA |
| 10/28/2008 02:49:30 PM | |
| Darunavir/Ritonavir Achieves Superiority Over Lopinavir/Ritonavir in Suppressing Human Immunodeficiency Virus: Presented at ICAAC/IDSA |
| 10/27/2008 03:39:03 PM | |
| Initiating Early Therapy for Human Immunodeficiency Virus Significantly Reduces Risk of Death: Presented at ICAAC/IDSA |
| 10/22/2008 01:19:19 PM | |
| Darunavir Receives Expanded Indication From FDA for Treatment-Naïve Adults |
| 10/21/2008 04:45:35 PM | |
| Markers of Inflammation, Blood-Clotting Tied to Hazards of Intermittent HIV Treatment |
| 10/17/2008 05:27:59 PM | |
| Combining Diagnostic Techniques Can Improve Surveillance and Follow-Up of Anal Intraepithelial Neoplasia in HIV Patients: Presented at ASCP |
| 10/14/2008 02:54:43 PM | |
| Efavirenz-Based Therapies Associated With Better Outcomes in HIV Patients in Developing Countries |
| 10/07/2008 04:40:13 PM | |
| Circumcision Not Associated With Reduced Risk of HIV for Men Who Have Sex With Men |
| 10/02/2008 12:40:06 PM | |
| Maraviroc Shows Efficacy Over 48 Weeks in Drug-Resistant Patients With R5 HIV |
| 10/02/2008 12:25:52 PM | |
| FDA Approves Atazanavir Boosted With Ritonavir for Treatment-Naïve HIV Patients |
| 09/17/2008 01:11:24 PM | |
| HIV-Infected Patients With Long-Term Viral Suppression Have Slower CD4 Recovery With Tenofovir Regimens: Presented at ACCP |
| 08/29/2008 01:10:42 PM | |
| Etravirine Approved in the European Union for HIV Combination Therapy |
| 08/28/2008 03:45:49 PM | |
| Fracture Prevalence Is Significantly Higher in HIV-Infected Patients |
| 08/20/2008 10:34:41 AM | |
| Leaky Gut Linked to HIV in Brain, Dementia |
| 08/10/2008 08:23:25 PM | |
| HIV Patients Resistant to Non-Nucleoside Reverse Transcriptase Inhibitors Experience Superior Results With Etravirine: Presented at AIDS 2008 |
| 08/10/2008 08:18:47 PM | |
| Outcome Data Disputed in Abacavir/Lamivudine Comparison Trial: Presented at AIDS 2008 |
| 08/09/2008 08:06:48 AM | |
| HIV Patients With High Viral Load Worsen on Fixed-Dose Abacavir/Lamivudine Compared With Fixed-Dose Tenofovir/Emtricitabine: Presented at AIDS 2008 |
| 08/08/2008 07:02:26 PM | |
| Combination of 3 New HIV Drugs Drives Virus to Undetectable Levels in Treatment-Experienced Patients: Presented at AIDS 2008 |
| 08/08/2008 05:28:28 PM | |
| Abacavir Linked to Heart Disease in Patients With HIV: Presented at AIDS 2008 |
| 08/08/2008 04:51:34 PM | |
| Atazanavir-Based Regimen Has Greater Risk of Treatment Failure Compared to Efavirenz-Based Combination: Presented at AIDS 2008 |
| 08/08/2008 04:49:33 PM | |
| Pharmacokinetic Interaction Between Anti-TB Agent Rifabutin and HIV Drug Rilpivirine: Presented at AIDS 2008 |
| 08/08/2008 04:45:32 PM | |
| Pregabalin No Better Than Placebo in Treating HIV-Associated Neuropathic Pain: Presented at AIDS 2008 |
| 08/08/2008 04:43:26 PM | |
| Antiretroviral Treatment Lowers Cardiovascular Risk in HIV+ Patients |
| 08/08/2008 04:41:23 PM | |
| Fixed-Dose Combination Tablets Simplify Antiretroviral Treatment for Children in India With HIV: Presented at AIDS 2008 |
| 08/08/2008 04:39:25 PM | |
| Fosamprenavir Offers Results Similar to Those of Other Protease Inhibitors When Patients With HIV Switch Regimens: Presented at AIDS 2008 |
| 08/08/2008 04:36:22 PM | |
| Incarcerated HIV Patients Have Similar Responses to Antiretrovirals as Other Populations: Presented at AIDS 2008 |
| 08/07/2008 04:26:29 PM | |
| Maraviroc Treatment Improves CD-Positive Cell Rebound in Patients With HIV: Presented at AIDS 2008 |
| 08/07/2008 04:21:30 PM | |
| Etravirine Suppresses HIV Viral Load With or Without Raltegravir or Darunavir Combination: Presented at AIDS 2008 |
| 08/07/2008 04:19:32 PM | |
| HIV Patients With Injection-Site Reactions Switched From Enfuvirtide to Raltegravir: Presented at AIDS 2008 |
| 08/07/2008 12:30:18 PM | |
| Switching From Stavudine to Efavirenz Maintains Long-Term Control of HIV, Improves Metabolic Profile: Presented at AIDS 2008 |
| 08/07/2008 12:28:32 PM | |
| Heterosexual HIV Infectivity Rate May Be Underestimated |
| 08/07/2008 12:23:45 PM | |
| Experimental Apricitabine Demonstrates Promising Safety at 24 Weeks: Presented at AIDS 2008 |
| 08/06/2008 05:12:52 PM | |
| Raltegravir Maintains Efficacy, Tolerability at 96 Weeks: Presented at AIDS 2008 |
| 08/06/2008 04:36:20 PM | |
| Investigative Rilpivirine Maintains Efficacy Against Efavirenz at 96 Weeks: Presented at AIDS 2008 |
| 08/05/2008 04:32:26 PM | |
| Antiretroviral Treatment During Pregnancy Effective in Preventing HIV Transmission From Mothers to Newborns: Presented at AIDS 2008 |
| 08/05/2008 04:27:41 PM | |
| Long-Term HIV Treatment May Reduce Risk for Atherosclerosis |
| 08/05/2008 04:14:14 PM | |
| Experimental Tesamorelin Reduces Abdominal Body Fat in Patients With HIV, Does Not Affect Glucose Tolerance: Presented at AIDS 2008 |
| 08/05/2008 04:12:20 PM | |
| Antiretroviral Therapy for Pregnant Women Causes Little Harm to Newborns: Presented at AIDS 2008 |